CPIX

Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company's lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients....

+See More

Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 4 April 2026